Piperidinyl-3-(aryloxy)propanamides and propanoates

Patent metadata

Field	Value
Publication number	US-12005054-B2
Application number	US-202117320574-A
Country	US
Kind code	B2
Filing date	May 14, 2021
Priority date	Mar 1, 2018
Publication date	Jun 11, 2024
Grant date	Jun 11, 2024

Abstract

Disclosed are compounds of Formula 1,

stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , R 12 , X 1 , X 2 , X 3 , X 4 , X 13 , and X 14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

First claim

What is claimed is:

1. A method of treating a disease, disorder or condition in a subject, the method comprising administering to the subject a compound of Formula 1,

or a pharmaceutically acceptable salt thereof in which:
X 1 is selected from N and CR 1 ;
X 2 is selected from N and CR 2 ;
X 3 is selected from N and CR 3 ; and
X 4 is selected from N and CR 4 , provided no more than two of X 1 , X 2 , X 3 , and X 4 are N;
X 13 is NR 13 and X 14 is CR 15 R 16 or X 13 is CH 2 and X 14 is NR 14 ;
L is selected from NR 8 and O;
r is selected from 0 and 1;
s is selected from 0 and 1;
R 1 , R 2 , and R 3 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

R 4 is selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

R 5 is selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo, oxo, and phenyl which is substituted with 0 to 3 optional substituents independently selected from halo; or

R 4 and R 5 , together with the carbon atoms to which they are attached, form a cyclopent-1-en-1,2-diyl or a furan-2,3-diyl;
R 6 and R 7 are each independently selected from halo and C 1-3 alkyl, or R 6 and R 7 , together with the carbon atom to which they are attached, form a C 3-4 cycloalkan-1,1-diyl;
R 8 is selected from H and C 1-4 alkyl;
R 9 and R 10 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano;
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

(c) phenyl and C 1-5 heteroaryl, each substituted with 0 to 3 optional substituents independently selected from halo, C 1-4 alkyl, and C 1-4 alkoxy, wherein the C 1-5 heteroaryl substituent is a monocyclic ring with 5 to 6 ring members in which 1 to 4 ring members are heteroatoms, each of the heteroatoms independently selected from N, O, and S, provided no more than one of the ring members is O or S, and wherein the C 1-4 alkyl and C 1-4 alkoxy optional substituents on phenyl and C 1-5 heteroaryl are each independently substituted with 0 to 3 optional substituents independently selected from halo; or
R 9 and R 10 , together with the carbon atom to which they are attached, form a C 3-4 cycloalkan-1,1-diyl;
R 11 and R 12 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

R 11 and R 12 , together with the carbon atom to which they are attached, form a C 3-4 cycloalkan-1,1-diyl;
R 13 and R 14 are each independently selected from
(a) hydrogen; and
(b) C 1-4 alkyl, which is un substituted or substituted with a substituent selected from cyano and oxo; and

R 15 and R 16 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

R 15 and R 16 , together with the carbon atom to which they are attached, form a C 3-4 cycloalkan-1,1-diyl;
wherein the disease, disorder or condition is pain.

2. The method according to claim 1 , wherein X 1 is CR 1 , X 2 is CR 2 , X 3 is CR 3 , and X 4 is CR 4 .

3. The method according to claim 2 , wherein R 1 , R 2 , R 3 , and R 4 are each independently selected from
(a) hydrogen, halo, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

4. The method according to claim 1 , wherein X 1 is N, X 2 is CR 2 , X 3 is CR 3 , and X 4 is CR 4 .

5. The method according to claim 4 , wherein R 2 , R 3 , and R 4 are each independently selected from
(a) hydrogen, halo, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

6. The method according to claim 1 , wherein R 5 is selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo, oxo, and phenyl which is substituted with 0 to 3 optional substituents independently selected from halo.

7. The method according to claim 1 , wherein R 6 and R 7 are each independently selected from fluoro and methyl or together with the carbon atom to which they are attached form a cyclopropan-1,1-diyl or a cyclobutan-1,1-diyl.

8. The method according to claim 1 , wherein each of R 6 and R 7 is methyl.

9. The method according to claim 1 , wherein L is NR 8 .

10. The method according to claim 9 , wherein R 8 is hydrogen.

11. The method according to claim 1 , wherein R 9 and R 10 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano;
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and
(c) phenyl and C 1-5 heteroaryl, each substituted with 0 to 3 optional substituents independently selected from halo, C 1-4 alkyl, and C 1-4 alkoxy, wherein the C 1-5 heteroaryl substituent is a monocyclic ring with 5 to 6 ring members in which 1 to 4 ring members are heteroatoms, each of the heteroatoms independently selected from N, O, and S, provided no more than one of the ring members is O or S, and wherein the C 1-4 alkyl and C 1-4 alkoxy optional substituents on phenyl and C 1-5 heteroaryl are each independently substituted with 0 to 3 optional substituents independently selected from halo.

12. The method according to claim 1 , wherein R 11 and R 12 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

13. The method according to claim 1 , wherein X 13 is NR 13 and X 14 is CR 15 R 16 .

14. The method according to claim 13 , wherein R 13 is selected from
(a) hydrogen; and
(b) C 1-4 alkyl, which is unsubstituted or substituted with a substituent selected from cyano and oxo.

15. The method according to claim 13 , wherein R 15 and R 16 are each independently selected from
(a) hydrogen, halo, hydroxy, and cyano; and
(b) C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

16. The method according to claim 1 , wherein r is 0.

17. The method according to claim 1 , wherein s is 0.

18. The method according to claim 1 , in which the compound is selected from the following compounds:
2,2-dimethyl-N-(1-methylpiperidin-4-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;
2

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Cheruvallath Zacharia
• Green Jason
• Johnson Ben
• Schleicher Kristin
• Sun Huikai
• Tang Mingnam

Classifications

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title